For the trial, over 90 healthy volunteers between the age of 18-30 will be exposed to a small amount of virus in a controlled environment. To put it in simple terms, the participants will be challenged by the virus to test the effectiveness of the vaccines.
For the trial, researchers will use the strain of the virus that has been circulating in the UK since March 2020, which is said to be of low risk for healthy young adults.
Reachers will also identify the smallest amount of virus that is required to infect the person.
The trials will be conducted jointly by the government’s Vaccines Taskforce, Imperial College London, the Royal Free London NHS Foundation Trust and the clinical company called hVIVO.